Lindahl, Hannes http://orcid.org/0000-0002-4447-9426
Vonlanthen, Sofie
Valentini, Davide
Björklund, Andreas T.
Sundin, Mikael http://orcid.org/0000-0002-9871-0961
Mielke, Stephan http://orcid.org/0000-0002-8325-9215
Hauzenberger, Dan
Funding for this research was provided by:
Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden
Article History
Received: 15 October 2021
Revised: 7 February 2022
Accepted: 8 February 2022
First Online: 24 February 2022
Competing interests
: Dan Hauzenberger is founder and co-owner of Devyser AB. He is also part-time employed by the company. Stephan Mielke has received speakers fee from Novartis and DNA Prime SA, has received travel support from and served in expert panel for Gilead/KITE, has received travel support and speakers fee from Celgene/BMS, has received research funding, travel support, and speakers fee from Kiadis Pharma, has served in expert panel for Bellicum, has received travel support and speakers fee from and has served in data safety monitoring board for Miltenyi, and has served in data safety monitoring board for Immunicum.